Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$46.75 USD

46.75
1,152,445

+0.47 (1.02%)

Updated Oct 1, 2024 04:00 PM ET

Pre-Market: $46.57 -0.18 (-0.39%) 8:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Corcept Therapeutics Focuses on Korlym's Label Expansion

We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.

    Why is Corcept's Stock Up More Than 60% So Far This Year?

    Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

      Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

      Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

        Nivalis' (NVLS) Shares Down After Merger Deal with Alpine

        The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.

          AMAG Files for FDA Approval of Subcutaneous Form of Makena

          AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.

            Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?

            Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Corcept (CORT) Strives to Commercialize Key Drug Korlym

              We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.

                Corcept Korlym Positive in Phase I/II Breast Cancer Study

                Corcept Therapeutics (CORT) announced encouraging efficacy data from a phase I/II study on Korlym in patients with metastatic triple-negative breast cancer.

                  Tirthankar Chakraborty headshot

                  New Strong Buy Stocks for September 21st

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                    Kevin Matras headshot

                    Explosive Stocks Under $10

                    Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include ARCO, CORT, EXEL, HL and LXP.

                      Arpita Dutt headshot

                      Pharma Industry Stock Outlook - March 2016

                      Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                        Arpita Dutt headshot

                        Pharma Industry Stock Outlook - March 2016

                        Looking at consensus earnings expectations, the Medical sector, which had performed well in 2015, is expected to see earnings growth of 0.7% and revenue growth of 7.7% in Q1.

                          David Bartosiak headshot

                          Bear of the Day: Jazz Pharma (JAZZ)

                          A little less JAZZ and a lot more blues has been playing lately